Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B-Reference-Cited by-同舟云学术

Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B

Published:2015-04-17 Issue:1 Volume:15 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Asad Mohammad,Bhattacharya Pradyot,Banerjee Antara,Ali Nahid

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/article/10.1186/s12879-015-0928-6/fulltext.html

Reference39 articles.

1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.

2. Goto H, Prianti M. Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo. 2009;51:241–6.

3. Md A, Ali N. Dynamicity of immune regulation during visceral leishmaniasis. Proc Indian Natl Sci Acad. 2014;80:247–67.

4. Bhattacharya P, Ali N. Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis. Rev Soc Bras Med Trop. 2013;46:128–34.

5. Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S, Ali N. Immune responses in kala-azar. Indian J Med Res. 2006;123:245–66.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomal dual delivery systems in visceral leishmaniasis enhance the synergistic effects of combination therapy: A promise for the future;Asian Pacific Journal of Tropical Medicine;2024-02

2. Liposome bilayer stability: emphasis on cholesterol and its alternatives;Journal of Liposome Research;2023-06-28

3. Amphotericin B Nano-Assemblies Circumvent Intrinsic Toxicity and Ensure Superior Protection in Experimental Visceral Leishmaniasis with Feeble Toxic Manifestation;Vaccines;2023-01-01

4. Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis—An updated review;Frontiers in Bioengineering and Biotechnology;2022-12-14

5. Amphotericin B: A drug of choice for Visceral Leishmaniasis;Acta Tropica;2022-11